ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back…
-Reductions in dysmenorrhea (DYS) and non-menstrual pelvic pain (NMPP), the co-primary efficacy endpoints, compared to placebo were observed for both doses after 1 and 2 months of…